GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Canbridge Pharmaceuticals Inc (HKSE:01228) » Definitions » Intangible Assets

Canbridge Pharmaceuticals (HKSE:01228) Intangible Assets : HK$77.1 Mil (As of Jun. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Canbridge Pharmaceuticals Intangible Assets?

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Canbridge Pharmaceuticals's intangible assets for the quarter that ended in Jun. 2024 was HK$77.1 Mil.


Canbridge Pharmaceuticals Intangible Assets Historical Data

The historical data trend for Canbridge Pharmaceuticals's Intangible Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Canbridge Pharmaceuticals Intangible Assets Chart

Canbridge Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intangible Assets
46.49 213.07 62.78 76.09 83.66

Canbridge Pharmaceuticals Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Intangible Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.83 76.09 91.21 83.66 77.10

Canbridge Pharmaceuticals Intangible Assets Calculation

Intangible assets are defined as identifiable non-monetary assets that cannot be seen, touched or physically measured. Examples of intangible assets include trade secrets, copyrights, patents, trademarks. If a company acquires assets at the prices above the book value, it may carry goodwill on its balance sheet. Goodwill reflects the difference between the price the company paid and the book value of the assets.


Canbridge Pharmaceuticals  (HKSE:01228) Intangible Assets Explanation

If a company (company A) received a patent through their own work, though it has value, it does not show up on its balance sheet as an intangible asset. However, if company A sells this patent to company B, it will show up on company B's balance sheet as an intangible asset.

The same applies to brand names, trade secrets etc. For instance, Coca-Cola's brand is extremely valuable, but the brand does not appear on its balance sheet, because the brand was never acquired.

Some intangibles are amortized. Amortization is the depreciation of intangible assets.

Many intangibles are not amortized. They may still be written down when the company decides the asset is impaired.

Whenever you see an increase in goodwill over a number of years, you can assume it's because the company is out buying other businesses above book value. GOOD if buying businesses with durable competitive advantage.

If goodwill stays the same, the company when acquiring other companies is either paying less than book value or not acquiring. Businesses with moats never sell for less than book value.

Intangibles acquired are on balance sheet at fair value.

Internally developed brand names (Coke, Wrigleys, Band-Aid) however are not reflected on the balance sheet.

One of the reasons competitive advantage power can remain hidden for so long.


Be Aware

Companies may change the way intangible assets are amortized, and this will affect their reported earnings.


Canbridge Pharmaceuticals Intangible Assets Related Terms

Thank you for viewing the detailed overview of Canbridge Pharmaceuticals's Intangible Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Canbridge Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
Building 21, No. 388 Xinping Street, Unit 18, 6th Floor, Suzhou Industrial Park, Suzhou, CHN
Canbridge Pharmaceuticals Inc is a biopharmaceutical company. It is committed to the research, development, and commercialization of biotech therapies targeting rare diseases and rare oncology. The company's core product in the rare oncology area CAN008, is a glycosylated CD95-Fc fusion protein being developed for the treatment of glioblastoma multiforme (GBM). In the rare disease area, the company have seven biologics and small molecules products and product candidates for the treatment of Hunter Syndrome (MPS II) and other lysosomal storage disorders (LSDs), complement mediated disorders, hemophilia A, metabolic disorders, and rare cholestatic liver diseases including ALGS, PFIC and BA. Its pipeline consists of biologics, small molecules, and gene therapy solutions and 13 drugs.
Executives
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2101 Beneficial owner
Xue James Qun 2101 Beneficial owner
Jpmorgan Chase & Co. 2201 Interest of corporation controlled by you
Athos Capital Limited 2102 Investment manager
Moskey Matthew Love 2201 Interest of corporation controlled by you
Schulte-hillen Friedrich Bela 2201 Interest of corporation controlled by you
Athos Asia Event Driven Master Fund 2101 Beneficial owner
Ctx Pharma Holdings Limited 2101 Beneficial owner
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse
Kolchinsky Peter 2305 Beneficiary of a trust
Ra Capital Management, L.p. 2102 Investment manager
Ra Capital Healthcare Fund Gp, Llc 2201 Interest of corporation controlled by you
Ra Capital Healthcare Fund, L.p. 2101 Beneficial owner

Canbridge Pharmaceuticals Headlines

No Headlines